Business Context and Reporting Period
This Form 8-K reports on the Special Meeting of Stockholders held by Aerpio Pharmaceuticals, Inc. on August 17, 2021. The filing details the voting results for five proposals submitted to shareholders. Note: The request metadata references "Whitehawk Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Aerpio Pharmaceuticals, Inc.
Key Financial Metrics
This filing is a current report regarding corporate governance and voting results. It does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Voting Results
Shareholders approved all five proposals submitted at the Special Meeting. A quorum was established with 33,092,898 shares present or represented out of 47,477,084 outstanding shares.
- Proposal 1 (Merger and PIPE Financing): Approved. Shareholders voted to issue Common Stock pursuant to the Merger Agreement with Aadi Bioscience, Inc., and to issue Common Stock and Pre-Funded Warrants under the PIPE Financing. This results in a change of control.
- Proposal 2 (Reverse Stock Split): Approved. Shareholders authorized an amended and restated certificate of incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-15.
- Proposal 3 (Incentive Award Plan): Approved. Shareholders voted to adopt a new incentive award plan.
- Proposal 4 (Employee Stock Purchase Plan): Approved. Shareholders voted to adopt an employee stock purchase plan.
- Proposal 5 (Adjournment): Approved. Shareholders authorized the adjournment of the meeting if necessary to solicit additional proxies for Proposals 1 and 2, though this was not required as sufficient votes were obtained.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors beyond the context of the merger and stock split. The primary contingency noted was the potential need to adjourn the meeting to secure votes for the merger and reverse split, which was rendered unnecessary by the final vote count.
Investor Verification Checklist
- Verify the final execution date and terms of the merger with Aadi Bioscience, Inc.
- Confirm the specific reverse stock split ratio selected by the Board within the authorized 1-for-5 to 1-for-15 range.
- Review the definitive terms of the PIPE Financing and the issuance of Pre-Funded Warrants.
- Check subsequent filings for the updated share count and ticker symbol changes following the merger and reverse split.